<DOC>
	<DOCNO>NCT01462396</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation explore patient high risk neuroblastoma . Results mixed , small series case report . Recent report , however , especially haploidentical transplantation encouraging . Eradication neuroblastoma may mediate component innate immune system ( natural killer cell ) adaptive immune system via T-cell cytotoxicity development humoral response tumor specific antigen minor histocompatibility antigen . To overcome restriction create unavailability Human leukocyte antigen ( HLA ) match donor , stem cell graft haploidentical related donor explore . Historically , use full haplotype mismatch family member donor limit development severe graft-versus-host disease high rate graft failure . Graft failure overcome increase immunosuppression increase number transplant stem cell . The effective mean graft versus host disease ( GVHD ) prophylaxis T cell depletion donor marrow . A 3-4 log depletion reduce risk develop significant GVHD le 10 % . Methods mobilize stem cell bone marrow peripheral blood collect stem cell apheresis increase availability stem cell magnitude . Selection device develop prepare extremely pure population CD34 cell upwards 5 log depletion contaminate T cell . The CliniMACS CD34 Reagent System medical device design select CD34+ hematopoietic cell heterogeneous hematologic cell population . The investigator intend provide mismatch relate hematopoietic stem cell transplantation 10 patient relapsed refractory neuroblastoma . Harnessing potential innate adaptive immune response allogeneic Hematopoietic stem cell transplantation ( HSCT ) may provide cure patient tumor .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Advanced Neuroblastoma Using MHC Mismatched Related Donors</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Age 6 month &lt; 18 year Measurable tumor routine image bone marrow biopsy Patient must 3/6 , 4/6 , 5/6 human leukocyte antigen ( HLA ) mismatch related donor EpsteinBarr virus ( EBV ) seropositive Karnofsky score 60 % great 10yrs old old , Lansky score 60 % great 10yrs old Pulse ox &gt; 90 % room air Recovered toxic effect prior chemotherapy Patient must pregnant Patient must HIV negative Patient responsible person must able understand sign inform consent Available donor without contraindication stem cell collection Pregnant lactate woman . Human immunodeficiency virus ( HIV ) positive patient . Uncontrolled intercurrent infection . Renal failure ( Creatine &gt; 1.5 Creatinine Clearance &lt; 40 ml/min/1.73m2 ) Active hepatitis cirrhosis liver test value great 3 time normal NOTE : Patients would exclude protocol strictly laboratory abnormality include investigator 's discretion , review Children 's Mercy Hospital ethic board Donor Inclusion/Exclusion Criteria Donor must good health base review system result physical examination , routine test per standard good medical care . Female donor childbearing age must negative pregnancy test must lactate EBv seropositive Donor stem cell human leukocyte antigen ( HLA ) type use molecular method . See section 6.1.3 HLA matching requirement .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>